To include your compound in the COVID-19 Resource Center, submit it here.

Priority Review for Kite's CAR T therapy

Kite Pharma Inc. (NASDAQ:KITE) said FDA accepted and granted Priority Review to a BLA for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE